Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04106557 · ClinicalTrials.gov registry record · Phase 3
A Study of OV101 in Individuals With Angelman Syndrome (AS)
A Phase 3 study, sponsored by Healx AI.
- Completed
- Registry status
- Phase 3
- Development phase
- 104
- Enrollment target
NCT04106557 is a Phase 3 study that has completed, run by Healx AI. The registered enrollment target is 104 participants.
The verdict
NCT04106557, a Phase 3 study, has completed, sponsored by Healx AI.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 104 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the efficacy and safety of oral OV101 (gaboxadol) in pediatric subjects with Angelman syndrome.
Interventions
- DRUG Placebo
- DRUG Gaboxadol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2019-09-09 |
| Est. Completion | 2020-11-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04106557
The ClinicalTrials.gov registry entry for NCT04106557 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 104 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Healx AI, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04106557 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04106557 about?
NCT04106557 is a clinical study titled "A Study of OV101 in Individuals With Angelman Syndrome (AS)". The purpose of this study is to assess the efficacy and safety of oral OV101 (gaboxadol) in pediatric subjects with Angelman syndrome.
What is the current status of trial NCT04106557?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 104 participants. The study started on 2019-09-09. Estimated completion is 2020-11-02.
What interventions are being tested in trial NCT04106557?
The interventions under investigation include: Placebo (DRUG), Gaboxadol (DRUG).
Who is sponsoring clinical trial NCT04106557?
This trial is sponsored by Healx AI, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.